	US 12,239,663 B2
	Pharmaceutical composition for prevention or treatment of lysosomal storage disorders
Kyung-Sun Kang, Seoul (KR); Byung Hee Hong, Suwon-si (KR); Insung Kang, Anyang-si (KR); Je Min Yoo, Seoul (KR); and Donghoon Kim, Seoul (KR)
Assigned to BIOGRAPHENE INC., Seoul (KR); and SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, Seoul (KR)
Appl. No. 17/310,400
Filed by BIOGRAPHENE INC., Seoul (KR); and SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, Seoul (KR)
PCT Filed Jan. 23, 2020, PCT No. PCT/KR2020/001162 § 371(c)(1), (2) Date Jul. 30, 2021, PCT Pub. No. WO2020/159159, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 10-2019-0011642 (KR), filed on Jan. 30, 2019.
Prior Publication US 2022/0096540 A1, Mar. 31, 2022
Int. Cl. A61K 33/44 (2006.01); A61K 9/14 (2006.01); A61P 3/06 (2006.01); B82Y 5/00 (2011.01); B82Y 20/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01); C01B 32/198 (2017.01); C09K 11/65 (2006.01)

CPC A61K 33/44 (2013.01) [A61K 9/14 (2013.01); A61P 3/06 (2018.01); C01B 32/198 (2017.08); C09K 11/65 (2013.01); B82Y 5/00 (2013.01); B82Y 20/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01); C01P 2004/04 (2013.01); C01P 2004/64 (2013.01); C01P 2006/60 (2013.01)]

4 Claims

1. A method for treating a lysosomal storage disorder, comprising administering to a subject having a lysosomal storage disorder a composition comprising graphene quantum dots as an active ingredient,

wherein the graphene quantum dots have a length of 1 nm to 20 nm,

wherein the graphene quantum dots comprise, as a terminal functional group, an oxygen atom-containing functional group selected from the group consisting of a carboxyl group, a ketone group, an aldehyde group, a hydroxy group, and an epoxy group, and

wherein the lysosomal storage disorder is Niemann-Pick disease or Gaucher disease.